Regeneron Pharmaceuticals (NASDAQ:REGN) has been given a $530.00 price target by analysts at Guggenheim in a note issued to investors on Friday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Guggenheim’s price target would indicate a potential upside of 57.56% from the company’s current price.
Several other brokerages also recently weighed in on REGN. BidaskClub upgraded Regeneron Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, January 26th. BMO Capital Markets set a $444.00 price objective on Regeneron Pharmaceuticals and gave the stock a “hold” rating in a report on Monday, November 27th. Citigroup downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $480.00 to $380.00 in a report on Friday, December 1st. Robert W. Baird upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “neutral” rating in a report on Friday, November 3rd. Finally, Argus reduced their price objective on Regeneron Pharmaceuticals from $540.00 to $470.00 and set a “buy” rating on the stock in a report on Thursday, December 28th. Four investment analysts have rated the stock with a sell rating, fourteen have given a hold rating and eleven have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $463.19.
Shares of Regeneron Pharmaceuticals (NASDAQ REGN) traded up $13.76 during midday trading on Friday, hitting $336.38. The stock had a trading volume of 1,957,392 shares, compared to its average volume of 950,286. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.07 and a current ratio of 2.14. Regeneron Pharmaceuticals has a 12-month low of $314.99 and a 12-month high of $543.55. The stock has a market capitalization of $37,680.00, a P/E ratio of 32.59, a price-to-earnings-growth ratio of 1.22 and a beta of 1.47.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Shell Asset Management Co. boosted its position in Regeneron Pharmaceuticals by 24.1% during the 3rd quarter. Shell Asset Management Co. now owns 15,435 shares of the biopharmaceutical company’s stock valued at $5,565,000 after acquiring an additional 2,999 shares in the last quarter. DnB Asset Management AS bought a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $9,136,000. Northpointe Capital LLC bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $2,089,000. Cubist Systematic Strategies LLC boosted its position in Regeneron Pharmaceuticals by 176.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 671 shares of the biopharmaceutical company’s stock valued at $330,000 after acquiring an additional 428 shares in the last quarter. Finally, Griffin Asset Management Inc. bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $1,579,000. 65.69% of the stock is currently owned by institutional investors and hedge funds.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.